Photo from Yuksel Urun/X
Apr 14, 2024, 10:45
Final pre-spectified overall survival analysis of CLEAR, a phase III study – summarized by Yuksel Urun
Yuksel Urun, Professor in Department of Medical Oncology at Ankara University School of Medicine, shared on X:
“Final pre-specified Overall Survival Analysis of CLEAR, a Phase III Study:
- Final CLEAR trial results: Lenvatinib and Pembrolizumab reduces mortality risk by 21% versus Sunitinib in advanced RCC.
- While median OS is similar, the combo’s lower HR and tight 95% CI underscore its robust benefit over time.
- Medians are just midpoints; consistent benefit and CI (Confidence Interval) matter most?
Any insights from the statistical point?”
Additional information.
Source: Yuksel Urun/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 8, 2024, 08:45
Nov 8, 2024, 04:44
Nov 7, 2024, 19:46
Nov 7, 2024, 19:43
Nov 7, 2024, 19:36
Nov 7, 2024, 19:32
Nov 7, 2024, 19:28
Nov 7, 2024, 19:24